Wellington Shields & Co’s Royalty Pharma RPRX Stock Holding History

Wellington Shields & Co’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-34,318	Closed	-$1.36M	–	308
2022 Q4	$1.36M	Sell	34,318 -53,559	-61%	-$2.24M	0.31%	44
2022 Q3	$3.53M	Hold	87,877	–	–	1.54%	12
2022 Q2	$3.69M	Hold	87,877	–	–	0.9%	12
2022 Q1	$3.42M	Hold	87,877	–	–	1.13%	19
2021 Q4	$3.5M	Sell	87,877 -3,293	-4%	-$128K	0.7%	22
2021 Q3	$3.29M	Hold	91,170	–	–	1.15%	19
2021 Q2	$3.74M	Sell	91,170 -2,500	-3%	-$106K	1.23%	13
2021 Q1	$4.09M	Sell	93,670 -1,000	-1%	-$47.4K	1.46%	11
2020 Q4	$4.74M	Buy	+94,670	New	+$4.02M	1.7%	11

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Shields & Co's RPRX Position: Q1 2023 in Review

Wellington Shields & Co sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 34,318 shares — an estimated $1.36M sold.

Wellington Shields & Co first reported a position in RPRX in Q4 2020 and held it in 9 quarters. The position peaked at $4.74M in Q4 2020. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

Wellington Shields & Co reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
Wellington Shields & Co sold 34,318 Royalty Pharma shares in Q1 2023, an estimated $1.36M.
Wellington Shields & Co first reported a position in Royalty Pharma in Q4 2020 and held it in 9 quarters.
Wellington Shields & Co's Royalty Pharma position peaked at $4.74M in Q4 2020.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Wellington Shields & Co's 13F filing for Q1 2023, filed 11 May 2023.